Navigation Links
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Date:6/17/2008

and ophthalmologic conditions. The committee provides non-binding recommendations based on its evaluation; however, final decisions on approval of the drug are made by the FDA.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, caused by the overproduction of skin cells, resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that 125 million people worldwide have psoriasis, including two percent of both the U.S. and European populations, or some 7.5 million Americans and 10 million Europeans. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe.

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in psoriasis.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, pediatric Crohn's disease and psoriasis.

The world leader in monoclonal antibody production and technology, Centocor has brought critical biologic therapies to patients suffering from debilitating immune disorders. Centocor is a whol
'/>"/>

SOURCE Centocor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
2. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
5. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
6. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
7. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
8. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
9. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
10. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
11. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... million milestone payment from Biogen Idec related to advancing ... in infants with spinal muscular atrophy (SMA).  ... Rx, is a randomized, double-blind, sham-procedure controlled thirteen ... The study will evaluate the efficacy and safety of ...
(Date:3/5/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology, and medical device industries, ... announced its financial results for the fourth quarter and ... , Net Revenues Increased 21.3% Year Over Year ... Grew 17.7% Year Over Year to $140.5 Million ...
(Date:3/5/2015)... , March 5, 2015  As the ... of regulations, Ethics & Compliance professionals are placing ... a new survey issued today by LRN, the ... education. An overwhelming majority of respondents expressed that ... most important component of E&C training programs (57%), ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 2Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 3Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 4Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3
... proof of concept for company,s first-in-class SERM designed ... with hormone therapy--CAMBRIDGE, Mass., March 24 Radius ... has been dosed in the company,s proof-of-concept Phase ... receptor modulator (SERM) undergoing clinical evaluation for treatment ...
... Own Power in Health Care Decisions?CHARLOTTE, N.C., March 24 ... vibrant and healthy life at any age, or to ... & Symposium may have the answers right in your ... year,s premier health and wellness event in the queen ...
Cached Medicine Technology:Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 2Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 3Anti-Aging Expo & Symposium Showcases in Charlotte on March 28th 2
(Date:3/6/2015)... (PRWEB) March 06, 2015 Ticket Down is ... Portland, Oregon at the Moda Center. After being ... Garth Brooks is showing no signs of letting up on ... country legend and his wife, Trisha Yearwood, to venues around ... be bringing their critically acclaimed tour to the Moda Center ...
(Date:3/6/2015)... As the Muscular Dystrophy Association continues to enhance ... hired two new Scientific Program Officers, Amanda Haidet-Phillips, Ph.D ... Grace Pavlath, Ph.D, who joined MDA late last year ... together will lead MDA as it accelerates new front-line ... types of neuromuscular and motor neuron diseases. ...
(Date:3/6/2015)... US Sports Football Camps expands its network ... non-contact specialty camps and one contact football camp. The ... located at Bowie State University and Riverdale Baptist School. ... speed and strength of football athletes. The contact football ... Graves, former quarterback in the Canadian Football League, as ...
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
(Date:3/6/2015)... GA (PRWEB) March 06, 2015 ... announced the release of a Clostridium Difficile (C ... providers. The C Diff use case is the ... that span hospital acquired infections, chronic conditions, and ... platform, the C Diff solution flags at risk ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... Ala., May 27 Leading fitness social network and tracking ... name to DailyBurn , effective immediately.In just ... community of more than 125,000 members, who have, depending on ... gained an average of 5.75 lbs of muscle using DailyBurn,s ...
... - New national survey reveals insights on treatment ... treatmentROCKLAND, Mass. and NEW YORK, May 27 ... with EMD Serono, today released findings from a ... Outlook on Emerging Therapies" in conjunction with the ...
... Practical Insights on Physician Engagement, Career SuccessSCOTTSDALE, Ariz., ... Corporation, whose Fusionfx solution suite aggregates ... single, clinically relevant views of patient information, today ... papers documenting the increasing involvement of healthcare chief ...
... at "A Chocolat au Vin Affair," St. Jude Inaugural Gala with ... 2009, 8:00pm, New York City. , ... (PRWEB) May ... the fight against childhood cancer by supporting St. Jude Children,s Research ...
... ), a comprehensive New Jersey anti-poverty charity, is experiencing an increase ... individual gifts -- Eva,s Village, Paterson, New Jersey, seeks additional funding ... ... (PRWEB) May 27, 2009 -- Eva,s Village describes an increase ...
... reducing their healthcare and insurance expenses during a hard-hitting ... ... Net implemented an across-the-board increase in California Medicare supplement insurance plan ... new ways to maximize healthcare dollars and minimize expenses says MedicareSupplementPlans.com., ...
Cached Medicine News:Health News:Gyminee Raises 525K and Relaunches as DailyBurn 2Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 2Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 3Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 4Health News:Multiple Sclerosis - What Are People With MS and Their Health Care Providers Really Thinking? 5Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 2Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 3Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 2Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 3Health News:Trusted Translations Launches "Translation for St. Jude" Initiative at St. Jude Gala in New York 4Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 2Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 3Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 4Health News:Eva's Village, a Comprehensive New Jersey Anti-Poverty charity, Seeks Additional Funding to Meet the Increasing Need Along with a Decline in Donations 5Health News:Seniors Seek to Reduce Healthcare Costs as Premiums Increase Says MedicareSupplementPlans.com 2
The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
... a revolutionary scientific breakthrough for controlling unsightly ... Cream permits you to spot reduce in ... can rid yourself of those unwanted lumps ... to your thigh, waist, tummy, or chin ...
... G5 Contour is a non-invasive massage ... nodes and the circulatory system. Extraordinary ... G5 Directional-Stroking action, which combines vertical ... and comfortable percussion, gyratory massage, deep ...
The Ritter 204 Manual Exam Table. Featuring the latest in design, comfort and functionality in a manual exam table, it truly offers efficient patient care....
Medicine Products: